Citations (20)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Aline de Oliveira Albuquerque, Haroldo Cid da Silva Junior, Geraldo Rodrigues Sartori & João Hermínio Martins da Silva. (2022) Computationally-obtained structural insights into the molecular interactions between Pidilizumab and binding partners DLL1 and PD-1. Journal of Biomolecular Structure and Dynamics 40:14, pages 6450-6462.
Read now
Read now
Weili Xue, Weiming Li, Tiantian Zhang, Zhaoming Li, Yingjun Wang, Yajuan Qiu, Yuanyuan Wang, Changying Chen, Dongjun Fu & Mingzhi Zhang. (2019) Anti-PD1 up-regulates PD-L1 expression and inhibits T-cell lymphoma progression: possible involvement of an IFN-γ-associated JAK-STAT pathway. OncoTargets and Therapy 12, pages 2079-2088.
Read now
Read now
Claire Vanpouille-Box, Claire Lhuillier, Lucillia Bezu, Fernando Aranda, Takahiro Yamazaki, Oliver Kepp, Jitka Fucikova, Radek Spisek, Sandra Demaria, Silvia C. Formenti, Laurence Zitvogel, Guido Kroemer & Lorenzo Galluzzi. (2017) Trial watch: Immune checkpoint blockers for cancer therapy. OncoImmunology 6:11.
Read now
Read now
Articles from other publishers (17)
Abid H. Banday & Mohnad Abdalla. (2023) Immune Checkpoint Inhibitors: Recent Clinical Advances and Future
Prospects. Current Medicinal Chemistry 30:28, pages 3215-3237.
Crossref
Crossref
Dae Young Lee, Eunji Im, Dahye Yoon, Young-Seob Lee, Geum-Soog Kim, Donghwi Kim & Sung-Hoon Kim. (2022) Pivotal role of PD-1/PD-L1 immune checkpoints in immune escape and cancer progression: Their interplay with platelets and FOXP3+Tregs related molecules, clinical implications and combinational potential with phytochemicals. Seminars in Cancer Biology 86, pages 1033-1057.
Crossref
Crossref
Layla Shojaie, Myra Ali, Andrea Iorga & Lily Dara. (2021) Mechanisms of immune checkpoint inhibitor-mediated liver injury. Acta Pharmaceutica Sinica B 11:12, pages 3727-3739.
Crossref
Crossref
Faroogh Marofi, Heshu Sulaiman Rahman, Muhammad Harun Achmad, Klunko Nataliya Sergeevna, Wanich Suksatan, Walid Kamal Abdelbasset, Maria Vladimirovna Mikhailova, Navid Shomali, Mahboubeh Yazdanifar, Ali Hassanzadeh, Majid Ahmadi, Roza Motavalli, Yashwant Pathak, Sepideh Izadi & Mostafa Jarahian. (2021) A Deep Insight Into CAR-T Cell Therapy in Non-Hodgkin Lymphoma: Application, Opportunities, and Future Directions. Frontiers in Immunology 12.
Crossref
Crossref
Mary Beth Seegars. (2021) Double Checkpoint Inhibitors in Autologous. Transplantation and Cellular Therapy 27:5, pages 357-358.
Crossref
Crossref
Giusy Elia, Silvia Martina Ferrari, Maria Rosaria Galdiero, Francesca Ragusa, Sabrina Rosaria Paparo, Ilaria Ruffilli, Gilda Varricchi, Poupak Fallahi & Alessandro Antonelli. (2020) New insight in endocrine-related adverse events associated to immune checkpoint blockade. Best Practice & Research Clinical Endocrinology & Metabolism 34:1, pages 101370.
Crossref
Crossref
Theodoulakis Christofi, Stavroula Baritaki, Luca Falzone, Massimo Libra & Apostolos Zaravinos. (2019) Current Perspectives in Cancer Immunotherapy. Cancers 11:10, pages 1472.
Crossref
Crossref
Silvia Martina Ferrari, Poupak Fallahi, Giusy Elia, Francesca Ragusa, Ilaria Ruffilli, Armando Patrizio, Maria Rosaria Galdiero, Enke Baldini, Salvatore Ulisse, Gianni Marone & Alessandro Antonelli. (2019) Autoimmune Endocrine Dysfunctions Associated with Cancer Immunotherapies. International Journal of Molecular Sciences 20:10, pages 2560.
Crossref
Crossref
Li-Yang Hu, Xiao-Lu Xu, Hui-Lan Rao, Jie Chen, Ren-Chun Lai, Hui-Qiang Huang, Wen-Qi Jiang, Tong-Yu Lin, Zhong-Jun Xia & Qing-Qing Cai. (2017) Expression and clinical value of programmed cell death-ligand 1 (PD-L1) in diffuse large B cell lymphoma: a retrospective study. Chinese Journal of Cancer 36:1.
Crossref
Crossref
Laurence P. Diggs & Eddy C. Hsueh. (2017) Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response. Biomarker Research 5:1.
Crossref
Crossref
Xinxin Zhu & Jinghe Lang. (2017) Soluble PD-1 and PD-L1: predictive and prognostic significance in cancer. Oncotarget 8:57, pages 97671-97682.
Crossref
Crossref
Jeong A. Park & Nai-Kong V. Cheung. (2017) Limitations and opportunities for immune checkpoint inhibitors in pediatric malignancies. Cancer Treatment Reviews 58, pages 22-33.
Crossref
Crossref
Yael Diesendruck & Itai Benhar. (2017) Novel immune check point inhibiting antibodies in cancer therapy—Opportunities and challenges. Drug Resistance Updates 30, pages 39-47.
Crossref
Crossref
Mei-Miao Zhan, Xue-Qin Hu, Xiu-Xiu Liu, Ban-Feng Ruan, Jun Xu & Chenzhong Liao. (2016) From monoclonal antibodies to small molecules: the development of inhibitors targeting the PD-1/PD-L1 pathway. Drug Discovery Today 21:6, pages 1027-1036.
Crossref
Crossref
Michael Coyle, Lale Kostakoglu & Andrew M. Evens. (2016) The evolving role of response-adapted PET imaging in Hodgkin lymphoma. Therapeutic Advances in Hematology 7:2, pages 108-125.
Crossref
Crossref
Rosalba Camicia, Hans C. Winkler & Paul O. Hassa. (2015) Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review. Molecular Cancer 14:1.
Crossref
Crossref
Lieping Chen & Xue Han. (2015) Anti?PD-1/PD-L1 therapy of human cancer: past, present, and future. Journal of Clinical Investigation 125:9, pages 3384-3391.
Crossref
Crossref